AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15843503 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal attentional bias to pain-related words
Number of subjects: 59
Study 15843503 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal attentional bias to pain-related words
Number of subjects: 59
Study 15843503 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal attentional bias to social threat-related words
Number of subjects: 59
Study 15843503 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal attentional bias to social threat-related words
Number of subjects: 59
Study 15843503 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional biases
Number of subjects: 59
Study 12946516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography of the elbow joint
Number of subjects: 320
Study 10999495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine at 1 atm
Number of subjects: 30
Study 10999495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine at 3 atm
Number of subjects: 30
Study 10999495 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 1 atm
Number of subjects: 30
Study 10999495 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 3 atm
Number of subjects: 30
Study 10999495 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth at 3 atm
Number of subjects: 30
Study 9186345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide plus orchiectomy
Number of subjects: 457
Study 9186345 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus orchiectomy
Number of subjects: 457
Study 1307883 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed method of drawing blood from arterial lines (n = 784)
Number of subjects: 1657
Study 1307883 — intervention group
Group type: COMPARATOR
Intervention: Open method of drawing blood from arterial lines (n = 873)
Number of subjects: 1657
Study 3839796 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin inhibitor (naproxen sodium)
Number of subjects: 139
Study 31862147 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 299
Study 31862147 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study 29335014 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN)
Number of subjects: 1343
Study 29335014 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 1343
Study 27323697 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (4 cm H2O)
Number of subjects: 25
Study 27323697 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (0 cm H2O)
Number of subjects: 25
Study 23592317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg) and Vitamin E (400 IU)
Number of subjects: 229
Study 23592317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 22909282 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng extract (1 g/day)
Number of subjects: 0
Study 22909282 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng extract (2 g/day)
Number of subjects: 0
Study 22909282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19785625 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 19
Study 19785625 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 19
Study 19076084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of indapamide retard with or without addition of 2‐4 mg of perindopril
Number of subjects: 3845
Study 16826016 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 22
Study 16826016 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 22
Study 12486423 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban with LMWH
Number of subjects: 5200
Study 12486423 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 5200
Study 12486423 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 5200
Study 10543284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (40 mg)
Number of subjects: 11
Study 10543284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8550646 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline immunosuppressive doses of glucocorticoids (10 mg of prednisone)
Number of subjects: 28
Study 2141247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammalian cell-derived recombinant DNA hepatitis B vaccine (Betagen)
Number of subjects: 800
Study 2141247 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived vaccine (Heptavax-B)
Number of subjects: 800
Study 6109234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloctaphenin (200 mg)
Number of subjects: 78
Study 6109234 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (200 mg)
Number of subjects: 78
Study 31948452 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Sexual and Reproductive Health Education (CSRHE) youth clubs
Number of subjects: 0
Study 29166321 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g low glycemic index modified starch supplement (UCAN)
Number of subjects: 10
Study 29166321 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g high glycemic index glucose‐based supplement (G)
Number of subjects: 10
Study 29166321 — intervention group
Group type: COMPARATOR
Intervention: Flavor‐matched noncaloric placebo (PL)
Number of subjects: 10
Study 27421617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy delivered by telephone (CBT-T)
Number of subjects: 141
Study 27421617 — intervention group
Group type: COMPARATOR
Intervention: Telephone-delivered nondirective supportive therapy (NST-T)
Number of subjects: 141
Study 25386945 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA) delivered by lay counselors
Number of subjects: 347
Study 25386945 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 347
Study 25386945 — intervention group
Group type: EXPERIMENTAL
Intervention: CETA
Number of subjects: 347
Study 25386945 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 347
Study 22852878 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multi-session telephone counseling with motivational enhancement delivered by study staff
Number of subjects: 0
Study 22852878 — intervention group
Group type: COMPARATOR
Intervention: Faxed or online referral to the New York State Quitline
Number of subjects: 0
Study 19936725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 2701
Study 19936725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 2701
Study 16899484 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHOZYME‐TB Complex Plus commercial ELISA kit measuring immunoglobulin G against 38‐kDa and 16‐kDa recombinant antigens
Number of subjects: 179
Study 16899484 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers and subjects with pulmonary diseases other than TB)
Number of subjects: 179
Study 15609278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 15609278 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide
Number of subjects: 0
Study 12175357 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam swabs
Number of subjects: 34
Study 12175357 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushes
Number of subjects: 34
Study 9570255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone metasulphobenzoate
Number of subjects: 24
Study 9570255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Number of subjects: 24
Study 7756935 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonozyme enzyme immunoassay
Number of subjects: 42
Study 7756935 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonozyme enzyme immunoassay (urine)
Number of subjects: 42
Study 7756935 — intervention group
Group type: COMPARATOR
Intervention: Gonozyme enzyme immunoassay (swabs)
Number of subjects: 42
Study 3195535 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (32 subjects)
Number of subjects: 98
Study 3195535 — intervention group
Group type: COMPARATOR
Intervention: Limited exertion program (37 subjects)
Number of subjects: 98
Study 29976173 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care Circulating Cathodic Antigen (POC-CCA) test integrated with praziquantel (PZQ) treatment.
Number of subjects: 450
Study 29976173 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (PZQ) treatment without testing.
Number of subjects: 450
Study 29976173 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care Circulating Cathodic Antigen (POC-CCA) test.
Number of subjects: 450
Study 27700210 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron-based gel
Number of subjects: 47
Study 27700210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 26159834 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive smartphone app
Number of subjects: 51
Study 26159834 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive smartphone app
Number of subjects: 51
Study 26159834 — intervention group
Group type: COMPARATOR
Intervention: Usual behavior (control)
Number of subjects: 51
Study 22788723 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-NT (no surface treatment)
Number of subjects: 30
Study 22788723 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-CO (surface silicatization with CoJet sand)
Number of subjects: 30
Study 22788723 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-ZP (zirconia surface treated with Z-Prime Plus)
Number of subjects: 30
Study 22788723 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-CO (surface silicatization with CoJet sand)
Number of subjects: 30
Study 22788723 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-ZP (zirconia surface treated with Z-Prime Plus)
Number of subjects: 30
Study 22788723 — intervention group
Group type: COMPARATOR
Intervention: AR (as received, control)
Number of subjects: 30
Study 22788723 — intervention group
Group type: EXPERIMENTAL
Intervention: AG (artificial aging)
Number of subjects: 30
Study 21492364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 0.5 mg daily
Number of subjects: 287
Study 21492364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.0 mg daily
Number of subjects: 287
Study 21492364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.5 mg daily
Number of subjects: 287
Study 21492364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 287
Study 21492364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 21492364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.0 mg and 1.5 mg
Number of subjects: 287
Study 19797185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Parallel Process modified poster
Number of subjects: 274
Study 19797185 — intervention group
Group type: COMPARATOR
Intervention: Standard educational poster (control)
Number of subjects: 274
Study 19797185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both posters (younger group)
Number of subjects: 274
Study 16377048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol challenge
Number of subjects: 22
Study 16377048 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol
Number of subjects: 22
Study 15609596 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prepared ear-dropping made by combined Chinese and Western drugs
Number of subjects: 64
Study 15609596 — intervention group
Group type: COMPARATOR
Intervention: Placebo ear-dropping
Number of subjects: 64
Study 11067720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 11067720 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study 11067720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11067720 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and Paroxetine
Number of subjects: 0
Study 9511077 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin
Number of subjects: 0
Study 9511077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfopristin
Number of subjects: 0
Study 9511077 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin and dalfopristin (combined)
Number of subjects: 0
Study 9511077 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0
Study 8638859 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel
Number of subjects: 0
Study 8638859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8638859 — intervention group
Group type: COMPARATOR
Intervention: Belief manipulation (active agent vs placebo)
Number of subjects: 0
Study 2513966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam elixir (0.3 mg/kg)
Number of subjects: 151
Study 2513966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular papaveretum with hyoscine (0.3 mg/kg with 0.006 mg/kg)
Number of subjects: 151
Study 2513966 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 151
Study 166586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (50 mg/m² body surface area, subcutaneously, once daily for 4 days)
Number of subjects: 60
Study 166586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine
Number of subjects: 60
Study 166586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31624391 — intervention group
Group type: EXPERIMENTAL
Intervention: CT three-dimensional reconstruction technique for guiding tracheal intubation (group E)
Number of subjects: 44
Study 31624391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fiber bronchoscopes shaped according to CT images (group E)
Number of subjects: 44
Study 31624391 — intervention group
Group type: COMPARATOR
Intervention: Rigid fiber bronchoscopes with original angles (group C)
Number of subjects: 44
Study 31624391 — intervention group
Group type: EXPERIMENTAL
Intervention: CT three-dimensional reconstruction technique (group E)
Number of subjects: 44
Study 28538759 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP maintained ≤ 15 cmH2O (G15)
Number of subjects: 140
Study 28538759 — intervention group
Group type: COMPARATOR
Intervention: CVP maintained ≤ 20 cmH2O (G20)
Number of subjects: 140
Study 24633388 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet and antithrombotic therapy (AP/AT)
Number of subjects: 5211
Study 24633388 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet and antithrombotic therapy (AP/AT)
Number of subjects: 5211
Study 22223598 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hyoscine‐N‐butylbromide
Number of subjects: 816
Study 22223598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study 22223598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hyoscine‐N‐butylbromide and placebo)
Number of subjects: 816
Study 20100962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 435
Study 17869448 — intervention group
Group type: EXPERIMENTAL
Intervention: d-threo-methylphenidate HCl (d-MPH)
Number of subjects: 68
Study 17869448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15859527 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional backward walking training (30 min, three times a week for three weeks)
Number of subjects: 25
Study 15859527 — intervention group
Group type: COMPARATOR
Intervention: Conventional training programme (40 min, three times a week for three weeks)
Number of subjects: 25
Study 12556949 — intervention group
Group type: EXPERIMENTAL
Intervention: Actimel (fermented milk preparation)
Number of subjects: 150
Study 12556949 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian Dahi (fermented milk preparation)
Number of subjects: 150
Study 12556949 — intervention group
Group type: COMPARATOR
Intervention: Ultra-heat-treated yoghurt preparation (control group)
Number of subjects: 150
Study 12556949 — intervention group
Group type: EXPERIMENTAL
Intervention: Actimel as a starter in community
Number of subjects: 150
Study 10354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Serial Visual Presentation (RSVP)
Number of subjects: 0
Study 10354807 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVP with a completion meter
Number of subjects: 0
Study 10354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence-by-sentence presentation
Number of subjects: 0
Study 10354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence-by-sentence presentation with a completion meter
Number of subjects: 0
Study 10354807 — intervention group
Group type: COMPARATOR
Intervention: Normal page condition
Number of subjects: 0
Study 8733313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (1000 kcal/day, casein based enteral nutritional formula)
Number of subjects: 23
Study 8733313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (using pressure threshold load valve at 30% of Maximal Inspiratory Mouth Pressure) with nutritional supplement
Number of subjects: 23
Study 8733313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (using pressure threshold load valve) without nutritional supplement
Number of subjects: 23
Study 8733313 — intervention group
Group type: COMPARATOR
Intervention: No training or nutritional supplement
Number of subjects: 23
Study 2665800 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 262
Study 2665800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 2665800 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (3 injections or more)
Number of subjects: 262
Study 2665800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 injections or more)
Number of subjects: 262
Study 2665800 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (24h to 6 days after entry)
Number of subjects: 262
Study 2665800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24h to 6 days after entry)
Number of subjects: 262
Study 2665800 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (before 34 weeks gestation, 3 injections or more)
Number of subjects: 262
Study 2665800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (before 34 weeks gestation, 3 injections or more)
Number of subjects: 262
Study 339045 — intervention group
Group type: EXPERIMENTAL
Intervention: +Cyanidanol-3
Number of subjects: 35
Study 339045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31631058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-synchronized rTMS
Number of subjects: 17
Study 31631058 — intervention group
Group type: COMPARATOR
Intervention: Modified iTBS
Number of subjects: 17
Study 31631058 — intervention group
Group type: COMPARATOR
Intervention: Random alpha phase control condition
Number of subjects: 17
Study 30664539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Cognitive Processing Therapy (CPT) and smoking cessation treatment
Number of subjects: 40
Study 30664539 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation treatment without CPT
Number of subjects: 40
Study 29211128 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteness HP ‐ FGM (35% hydrogen peroxide)
Number of subjects: 53
Study 29211128 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteness HP Blue Calcium ‐ FGM (35% hydrogen peroxide)
Number of subjects: 53
Study 29211128 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteness HP Blue Calcium ‐ FGM (20% hydrogen peroxide)
Number of subjects: 53
Study 29211128 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 53
Study 25140039 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (A) 40 mg/day
Number of subjects: 119
Study 25140039 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus Temozolomide (AT)
Number of subjects: 119
Study 25140039 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (T) 75 mg/m2 for 21 of 28 days
Number of subjects: 119
Study 24024757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate suspension 20 mL three times a day
Number of subjects: 195
Study 24024757 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 195
Study 21619980 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 200
Study 21619980 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (CPB)
Number of subjects: 200
Study 19386025 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS-LBPV
Number of subjects: 72
Study 19386025 — intervention group
Group type: COMPARATOR
Intervention: TIPS-RBPV
Number of subjects: 72
Study 16762764 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) in patients with Takayasu's arteritis
Number of subjects: 14
Study 16762764 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without aortic disease defined by TEE
Number of subjects: 14
Study 15328899 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg titrated to 5 mg)
Number of subjects: 24
Study 15328899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11086300 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2 lakh units of Vitamin A orally (experimental group)
Number of subjects: 109
Study 11086300 — intervention group
Group type: COMPARATOR
Intervention: No Vitamin A supplementation (control group)
Number of subjects: 109
Study 9545677 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity strength training (EXH: 2 sets of 8 to 10 repetitions for 75 to 85% of 1 RM)
Number of subjects: 42
Study 9545677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity strength training (EXL: 2 sets of 14 to 16 repetitions for 55 to 65% of 1 RM)
Number of subjects: 42
Study 9545677 — intervention group
Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 42
Study 8164614 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (50 mg/day)
Number of subjects: 24